"1"^^ . "Sou\u010Dasn\u00FD pohled na pneumokokov\u00E9 konjugovan\u00E9 vakc\u00EDny"@cs . . "CZ - \u010Cesk\u00E1 republika" . . "Klinick\u00E1 mikrobiologie a infek\u010Dn\u00ED l\u00E9ka\u0159stv\u00ED" . . "Sou\u010Dasn\u00FD pohled na pneumokokov\u00E9 konjugovan\u00E9 vakc\u00EDny" . "[D7CF163B80C1]" . "G44" . . "500489" . . . "12" . "Pneumokokov\u00E1 onemocn\u011Bn\u00ED jsou p\u0159\u00ED\u010Dinou podstatn\u00E9 \u010D\u00E1sti nemocnosti a \u00FAmrtnosti jak v rozvinut\u00FDch tak rozvojov\u00FDch zem\u00EDch. Jedinou mo\u017Enou cestou kontroly jejich v\u00FDskytu je imunizace. Polyvalentn\u00ED polysacharidov\u00E9 vakc\u00EDny doporu\u010Dovan\u00E9 pro star\u0161\u00ED a chronicky nemocn\u00E9 v\u0161ak nejsou \u00FA\u010Dinn\u00E9 u d\u011Bt\u00ED do dvou let v\u011Bku. Toto omezen\u00ED m\u016F\u017Ee b\u00FDt p\u0159ekon\u00E1no nakonjugov\u00E1n\u00EDm polysacharid\u016F na proteinov\u00FD nosi\u010D, kter\u00FD obsahuje T-bun\u011B\u010Dn\u00E9 epitopy. Prvn\u00ED konjugovan\u00E1 pneumokokov\u00E1 vakc\u00EDna byla licensov\u00E1na v USA v \u00FAnoru 2000 jako 7valentn\u00ED vakc\u00EDna konjugovan\u00E1 na protein CRM197. Za\u010Dlen\u011Bn\u00ED do vakcina\u010Dn\u00EDho kalend\u00E1\u0159e vedlo k trval\u00E9mu sn\u00ED\u017Een\u00ED invaz\u00EDvn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED o t\u00E9m\u011B\u0159 80% a limitovan\u00E9mu \u00FA\u010Dinku na z\u00E1n\u011Bt st\u0159edn\u00EDho ucha. Pokryt\u00ED serotyp\u016F a n\u00E1hrada vakcina\u010Dn\u00EDch serotyp\u016F obzvl\u00E1\u0161t\u011B serotypem 19A jsou hlavn\u00ED omezuj\u00EDc\u00ED faktory pro glob\u00E1ln\u00ED pou\u017Eit\u00ED. Nov\u00E1 kandid\u00E1tn\u00ED 9valentn\u00ED vakc\u00EDna prok\u00E1zala podstatn\u00E9 sn\u00ED\u017Een\u00ED celkov\u00E9 nemocnosti v Gambii a 11valentn\u00ED vakc\u00EDna potvrdila zlep\u0161en\u00FD efekt na akutn\u00ED z\u00E1n\u011Bt st\u0159edn\u00EDho ucha."@cs . . "Sou\u010Dasn\u00FD pohled na pneumokokov\u00E9 konjugovan\u00E9 vakc\u00EDny" . . . . . "RIV/60162694:G44__/06:00001585!RIV07-MO0-G44_____" . . . "Z(MO0FVZ0000502)" . "5"^^ . "1211-264X" . "Acute otitic media; Conjugate pneumococcal vaccine"@en . . "Pneumokokov\u00E1 onemocn\u011Bn\u00ED jsou p\u0159\u00ED\u010Dinou podstatn\u00E9 \u010D\u00E1sti nemocnosti a \u00FAmrtnosti jak v rozvinut\u00FDch tak rozvojov\u00FDch zem\u00EDch. Jedinou mo\u017Enou cestou kontroly jejich v\u00FDskytu je imunizace. Polyvalentn\u00ED polysacharidov\u00E9 vakc\u00EDny doporu\u010Dovan\u00E9 pro star\u0161\u00ED a chronicky nemocn\u00E9 v\u0161ak nejsou \u00FA\u010Dinn\u00E9 u d\u011Bt\u00ED do dvou let v\u011Bku. Toto omezen\u00ED m\u016F\u017Ee b\u00FDt p\u0159ekon\u00E1no nakonjugov\u00E1n\u00EDm polysacharid\u016F na proteinov\u00FD nosi\u010D, kter\u00FD obsahuje T-bun\u011B\u010Dn\u00E9 epitopy. Prvn\u00ED konjugovan\u00E1 pneumokokov\u00E1 vakc\u00EDna byla licensov\u00E1na v USA v \u00FAnoru 2000 jako 7valentn\u00ED vakc\u00EDna konjugovan\u00E1 na protein CRM197. Za\u010Dlen\u011Bn\u00ED do vakcina\u010Dn\u00EDho kalend\u00E1\u0159e vedlo k trval\u00E9mu sn\u00ED\u017Een\u00ED invaz\u00EDvn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED o t\u00E9m\u011B\u0159 80% a limitovan\u00E9mu \u00FA\u010Dinku na z\u00E1n\u011Bt st\u0159edn\u00EDho ucha. Pokryt\u00ED serotyp\u016F a n\u00E1hrada vakcina\u010Dn\u00EDch serotyp\u016F obzvl\u00E1\u0161t\u011B serotypem 19A jsou hlavn\u00ED omezuj\u00EDc\u00ED faktory pro glob\u00E1ln\u00ED pou\u017Eit\u00ED. Nov\u00E1 kandid\u00E1tn\u00ED 9valentn\u00ED vakc\u00EDna prok\u00E1zala podstatn\u00E9 sn\u00ED\u017Een\u00ED celkov\u00E9 nemocnosti v Gambii a 11valentn\u00ED vakc\u00EDna potvrdila zlep\u0161en\u00FD efekt na akutn\u00ED z\u00E1n\u011Bt st\u0159edn\u00EDho ucha." . "Pneumococcal diseases cause substantial morbidity and mortality in both developed and developing countries. The only possible way how to control their occurrence is immunization. Multivalent plain polysaccharide vaccines recommended for elderly and chronically ill are however not effective in children under 2 years of age. This limitation can be overcome by coupling polysaccharides to a protein carrier that contains T-cell epitopes. The first pneumococcal conjugate vaccine was licensed in US in February 2000 as 7-valent vaccine conjugated on CRM197 protein. Implementation into immunization calendar resulted in sustainable reduction of invasive pneumococcal diseases by almost 80% and moderate effect on acute otitis media. Serotype coverage and replacement of vaccine serotype particularly by serotype 19A are the major limiting factors for global use. New candidate 9-valent vaccine proved significant reduction in overall morbidity in Gambia and 11-valent vaccine confirmed improved effect on acute otitis"@en . "98-102" . "Present view of conjugated pneumococcus vaccines"@en . "Sou\u010Dasn\u00FD pohled na pneumokokov\u00E9 konjugovan\u00E9 vakc\u00EDny"@cs . "Prymula, Roman" . "Present view of conjugated pneumococcus vaccines"@en . "RIV/60162694:G44__/06:00001585" . "3" . "1"^^ .